by Hemophilia Treatment Drugs Market – Snapshot
The global hemophilia treatment drugs market was valued at US$ 9,500 Mn in 2017 and is anticipated to reach US$ 15,000 Mn by 2026, expanding at a CAGR of 5% from 2018 to 2026. Increase in R&D investment by key players for developing new drugs for the treatment of hemophilia and rise in demand for long-acting replacement therapies and non-factor therapies are anticipated to fuel the growth of the global market during the forecast period. North America dominated the global market in 2017 owing to the introduction and uptake of new long-acting factors and alternative coagulation promoters and increase in the rate of diagnosis for hemophilia.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111972
The global hemophilia treatment drugs market is driven by government initiatives such as nationwide network of hemophilia treatment centers (HTCs) funded by the Federal Government in the U.S. Many of the HTCs are located at major university medical and research centers. The Federal Government in the U.S. provides funds for more than 100 HTCs. Treatment, education, and support are provided by medical experts at these HTCs. Patients who are provided care and treated at HTCs are less likely to have hospitalization and bleeding complications than those who avail care elsewhere.
The global hemophilia treatment drugs market has been segmented based on product type, disease indication, distribution channel, and region. In terms of product type, the recombinant coagulation factor concentrates segment is projected to account for significant share of the market during the forecast period. New recombinant pipeline agents and gene therapies, such as Fitusiran (phase III trials) and valoctocogene roxaparvovec (phase III candidate), are expected to gain market share during the forecast period. However, some products such as CSL-689 (phase II/III for hemophilia A and hemophilia B) are likely to account for small market share, as these are positioned as on-demand treatments in a market that is increasingly moving toward prophylaxis.
In terms of disease, the global hemophilia treatment drugs market has been classified into hemophilia A, hemophilia B, and others. The hemophilia A segment accounted for major share of the global hemophilia treatment drugs market in 2017. According to the Centers for Disease Control and Prevention (CDC), the exact number of people living with hemophilia globally is not known; however, hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia A each year. In terms of distribution channel, the global hemophilia treatment drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held major market share in 2017. The segment is likely to account for leading share of the market during the forecast period.
In terms of region, the global hemophilia treatment drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe accounted for major shares of the global hemophilia treatment drugs market in 2017 and the trend is likely to continue from 2018 to 2026. High rate of immigration from tropical regions, increase in health care budgets by governments, and government initiatives to promote hemophilia treatment contributed to the leading shares of these regions. Asia Pacific is projected to be the most attractive market for hemophilia treatment drugs during the forecast period. The market in Asia Pacific is expected to expand at a high CAGR from 2018 to 2026 due to large number of hemophilia patients opting for recombinant coagulation factor concentrates in developing countries such as India and China. The market in Latin America is poised to expand at a moderate growth rate during the forecast period.
Prominent players operating in the global hemophilia treatment drugs market include Pfizer, Inc., CSL Behring, Kedrion, Shire plc, Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., and Sanofi. Shire plc accounted for the largest market share in 2017. The company’s dominance of the market is due to its broad product portfolio, extensive geographical presence, and aggressive acquisition strategies. Shire plc strengthened its market position by acquiring Baxalta in June 2016. Baxalta is a key player in the rare diseases and other specialized disorders segments.
Novo Nordisk A/S accounted for the second largest share of the global hemophilia treatment drugs market in 2017 due to wide range of hemophilia drugs and robust pipeline. However, F. Hoffmann-La Roche, a new entrant in the hemophilia treatment drugs market, is expected to outperform Novo Nordisk during the forecast period. Pfizer held the third largest share of the hemophilia treatment drugs market in 2017.
Rising Danger of Hemophilia Cases will Bring Profitable Growth for the Hemophilia Treatment Drugs Market
The hemophilia treatment drugs market is expected to gain tremendous growth opportunities on the back of the rising cases of hemophilia across the globe. The growing number of cases related to hemophilia around the world will serve as a prominent growth factor during the assessment period of 2018-2026.
Hemophilia is a bleeding disorder. In this condition, a person’s blood does not clot properly which leads to many problems such as spontaneous bleeding and others. This disease is most prevalent among men. Drugs approved for the treatment of hemophilia are known as hemophilia treatment drugs.
According to the Centers for Disease Control and Prevention (CDC), about 400 babies are born with hemophilia A in the U.S. Nearly 33000 males are living with the disorder in the U.S. as per the survey by the CDC. The rising number of patients with hemophilia is directly proportional to the growth of the hemophilia treatment drugs market.
Research and development activities have a vital role in the growth of the hemophilia treatment drugs market. The players in the hemophilia treatment drugs market invest heavily in these activities for developing new formulations that are beneficial for the patients and treat hemophilia more easily and rapidly. Such formulations help in boosting the revenues of the players in the hemophilia treatment drugs market, eventually increasing the growth rate.
Strategic collaborations also play a major role in the growth of the hemophilia treatment drugs market. The players in the hemophilia treatment drugs market indulge in these activities for strengthening their foothold, ultimately increasing the growth prospects across the hemophilia treatment drugs market.
Quick approvals for drugs from regulatory authorities are proving to be game-changers for the hemophilia treatment drugs market. The increasing efforts of the government bodies of numerous countries to provide advanced therapies for hemophilia may also bring immense growth opportunities.
The global hemophilia treatment drugs market has been segmented as follows:
Product
- Recombinant coagulation factor concentrates
- Factor VIII
- Factor IX
- Others
- Plasma-derived coagulation factor concentrates
- Factor VIII
- Factor IX
- Others
- Others
Disease Indication
- Hemophilia A
- Hemophilia B
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- India
- China
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- GCC countries
- Rest of MEA
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111972/2900
